

Non Small-Cell Lung Cancer Market - 2022-2031

<https://marketpublishers.com/r/N0904F7AD48BEN.html>

Date: November 2025

Pages: 220

Price: US\$ 2,999.00 (Single User License)

ID: N0904F7AD48BEN

Abstracts

The Non Small-Cell Lung Cancer Market was valued at USD 25.4 billion in 2022 and is anticipated to reach USD 47.4 billion by 2031, at a CAGR of 0.084 from 2026 to 2032.

The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Non Small-Cell Lung Cancer Market.

This report delivers a comprehensive overview of the Non Small-Cell Lung Cancer Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Non Small-Cell Lung Cancer Market. The Non Small-Cell Lung Cancer Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2022–2031.

Non Small-Cell Lung Cancer Market Scope:

By Drug Class

Epidermal Growth Factor Receptor (EGFR) Inhibitors

Anaplastic Lymphoma Kinase (ALK) Inhibitors

ROS1 Inhibitors

BRAF Inhibitors

Others

By Type

Squamous Cell Carcinoma

Large Cell Carcinoma

Adenocarcinoma

Others

By Treatment

Chemotherapy

Targeted Therapy

Immunotherapy

By End-user

Hospitals

Homecare

Specialty Clinics

Others

Key Players

Eli Lilly and Company

Sanofi

Novartis AG

F. Hoffmann-La Roche Ltd

Merck & Co., Inc.

Pfizer Inc.

AstraZeneca

Boehringer Ingelheim

Bristol-Myers Squibb Company

Astellas

Major Highlights

This report delivers a comprehensive overview of the Non Small-Cell Lung Cancer Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Non Small-Cell Lung Cancer Market. The Non Small-Cell Lung Cancer Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2022–2031.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Regional Analysis:

North America (U.S., Canada, Mexico)

Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

South America (Colombia, Brazil, Argentina, Rest of South America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Partner Identification

Increase Your Customer Base by 3X using our Partner Identification tool

Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.

Identify high potential M&A targets based on synergies, market positioning and growth trajectory.

Prioritize partners by strategic fit rather than general capability.

Why Choose DataM?

Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.

Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.

White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.

Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.

Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.

Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

Target Audience 2026

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

Contents

1. METHODOLOGY AND SCOPE

- 1.1. Research Methodology
- 1.2. Research Objective and Scope of the Report

2. DEFINITION AND OVERVIEW

3. EXECUTIVE SUMMARY

- 3.1. Snippet by Drug Class
- 3.2. Snippet by Type
- 3.3. Snippet by Treatment
- 3.4. Snippet by End-user
- 3.5. Snippet by Region

4. DYNAMICS

- 4.1. Impacting Factors
 - 4.1.1. Drivers
 - 4.1.1.1. Rising FDA Approval for non-small-cell lung cancer treatment
 - 4.1.2. Restraints
 - 4.1.2.1. Side effects associated with non-small-cell lung cancer
 - 4.1.3. Opportunity
 - 4.1.3.1. Increasing research activities
 - 4.1.4. Impact Analysis

5. INDUSTRY ANALYSIS

- 5.1. Porter's 5 Forces Analysis
- 5.2. Supply Chain Analysis
- 5.3. Unmet Needs
- 5.4. Regulatory Analysis

6. COVID-19 ANALYSIS

- 6.1. Analysis of COVID-19
 - 6.1.1. Scenario Before COVID-19

- 6.1.2. Scenario During COVID-19
- 6.1.3. Scenario Post COVID-19
- 6.2. Pricing Dynamics Amid COVID-19
- 6.3. Demand-Supply Spectrum
- 6.4. Government Initiatives Related to the Market During the Pandemic
- 6.5. Manufacturers' Strategic Initiatives
- 6.6. Conclusion

7. RUSSIA-UKRAINE WAR ANALYSIS

8. ARTIFICIAL INTELLIGENCE ANALYSIS

9. BY DRUG CLASS

- 9.1. Introduction
 - 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
 - 9.1.2. Market Attractiveness Index, By Drug Class
- 9.2. Epidermal Growth Factor Receptor (EGFR) Inhibitors*
 - 9.2.1. Introduction
 - 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 9.3. Anaplastic Lymphoma Kinase (ALK) Inhibitors
- 9.4. ROS1 Inhibitors
- 9.5. BRAF Inhibitors
- 9.6. Others

10. BY TYPE

- 10.1. Introduction
 - 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
 - 10.1.2. Market Attractiveness Index, By Type
- 10.2. Squamous Cell Carcinoma*
 - 10.2.1. Introduction
 - 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 10.3. Large Cell Carcinoma
- 10.4. Adenocarcinoma
- 10.5. Others

11. BY TREATMENT

11.1. Introduction

11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment

11.1.2. Market Attractiveness Index, By Treatment

11.2. Chemotherapy*

11.2.1. Introduction

11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

11.3. Targeted Therapy

11.4. Immunotherapy

12. BY END-USER

12.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user

12.2. Market Attractiveness Index, By End-user

12.3. Hospitals*

12.3.1. Introduction

12.3.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

12.4. Homecare

12.5. Specialty Clinics

12.6. Others

13. BY REGION

13.1. Introduction

13.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region

13.1.2. Market Attractiveness Index, By Region

13.2. North America

13.2.1. Introduction

13.2.2. Key Region-Specific Dynamics

13.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class

13.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type

13.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment

13.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user

13.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

13.2.7.1. U.S.

13.2.7.2. Canada

13.2.7.3. Mexico

13.3. Europe

13.3.1. Introduction

13.3.2. Key Region-Specific Dynamics

- 13.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
- 13.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 13.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
- 13.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
- 13.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
 - 13.3.7.1. Germany
 - 13.3.7.2. U.K.
 - 13.3.7.3. France
 - 13.3.7.4. Italy
 - 13.3.7.5. Spain
 - 13.3.7.6. Rest of Europe
- 13.4. South America
 - 13.4.1. Introduction
 - 13.4.2. Key Region-Specific Dynamics
 - 13.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
 - 13.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
 - 13.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
 - 13.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
 - 13.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
 - 13.4.7.1. Brazil
 - 13.4.7.2. Argentina
 - 13.4.7.3. Rest of South America
- 13.5. Asia-Pacific
 - 13.5.1. Introduction
 - 13.5.2. Key Region-Specific Dynamics
 - 13.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
 - 13.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
 - 13.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
 - 13.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
 - 13.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
 - 13.5.7.1. China
 - 13.5.7.2. India
 - 13.5.7.3. Japan
 - 13.5.7.4. Australia
 - 13.5.7.5. Rest of Asia-Pacific
- 13.6. Middle East and Africa
 - 13.6.1. Introduction
 - 13.6.2. Key Region-Specific Dynamics
 - 13.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class

- 13.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 13.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
- 13.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user

14. COMPETITIVE LANDSCAPE

- 14.1. Competitive Scenario
- 14.2. Product Benchmarking
- 14.3. Company Share Analysis
- 14.4. Key Developments and Strategies

15. COMPANY PROFILES

- 15.1. Eli Lilly and Company*
 - 15.1.1. Company Overview
 - 15.1.2. Product Portfolio and Description
 - 15.1.3. Financial Overview
 - 15.1.4. Key Developments
- 15.2. Sanofi
- 15.3. Novartis AG
- 15.4. F. Hoffmann-La Roche Ltd
- 15.5. Merck & Co., Inc.
- 15.6. Pfizer Inc.
- 15.7. AstraZeneca
- 15.8. Boehringer Ingelheim
- 15.9. Bristol-Myers Squibb Company
- 15.10. Astellas (*LIST NOT EXHAUSTIVE)

16. APPENDIX

- 16.1. About Us and Services
- 16.2. Contact Us

I would like to order

Product name: Non Small-Cell Lung Cancer Market - 2022-2031

Product link: <https://marketpublishers.com/r/N0904F7AD48BEN.html>

Price: US\$ 2,999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/N0904F7AD48BEN.html>